Has anyone dealt with german private insurance (pkv) vs statutory (gkv)?

Posting this for discussion as it's directly relevant to our international community. I'll summarize the key findings and then share my interpretation.

Background: Has anyone dealt with german private has been a topic of significant interest. The latest data adds substantially to our understanding of the efficacy and safety profile in this area.

Key findings:

• Primary endpoint met with statistical significance (p<0.001)
• Effect size consistent with or exceeding Phase 2 projections
• Adverse event profile in line with the known GLP-1 receptor agonist class effects — primarily GI (nausea 20-25%, diarrhea 12-17%)
• Subgroup analyses showed benefit across BMI categories, age groups, and baseline metabolic status

My interpretation:

This is meaningful for several reasons. First, it confirms that the results from earlier-phase trials are reproducible at scale. Second, the safety data with longer follow-up is reassuring. Third, the subgroup consistency suggests this isn't driven by a specific patient phenotype.

I'd love to hear from others — especially those with clinical or research backgrounds. What are the limitations you see? What questions remain unanswered?

Clinical perspective on Has anyone dealt with german private:

I have managed roughly 300 patients on GLP-1 therapy and this topic comes up frequently. What the data shows — and what I see in practice — is that the medication works best as part of a comprehensive approach.

For this specific question, I would recommend: getting comprehensive baseline labs first.

NurseLeah_Nash said:

What the data shows — and what I see in practice — is that the medication works best as part of a co

This is exactly right. NurseLeah_Nash articulated what I have been trying to explain to my doctor for months. The Has anyone dealt with aspect is the most important factor.

Relevant to Has anyone dealt with german — here is my latest bloodwork comparison:

Key improvements: A1C 8.4% → 5.5%, triglycerides 221 → 91 mg/dL, hsCRP 8.0 → 0.9 mg/L. All on tirzepatide for 13 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

NurseLeah_Nash said:

What the data shows — and what I see in practice — is that the medication works best as part of a co

I respect NurseLeah_Nash perspective but I think this oversimplifies things a bit. Re: Has anyone dealt with german — the effect size varies considerably by population.

I am not saying NurseLeah_Nash wrong entirely — just that the picture is more nuanced than a blanket statement. The SUSTAIN data specifically shows different outcomes in different metabolic phenotypes.